¼¼°èÀÇ ÁßÁõ ÇÏÁöÇãÇ÷ Ä¡·á ½ÃÀå
Critical Limb Ischemia Treatment
»óǰÄÚµå : 1779886
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 375 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,209,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,629,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÁßÁõ ÇÏÁöÇãÇ÷ Ä¡·á ½ÃÀåÀº 2030³â±îÁö 81¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 56¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÁßÁõ ÇÏÁöÇãÇ÷ Ä¡·á ½ÃÀåÀº 2024-2030³â¿¡ CAGR 6.5%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 81¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀΠâ»ó°ü¸®¿ë µå·¹½ÌÀº CAGR 4.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 28¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »ý¹°Á¦Á¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 8.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 15¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÁßÁõ ÇÏÁöÇãÇ÷ Ä¡·á ½ÃÀåÀº 2024³â¿¡ 15¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 16¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 9.8%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.3%¿Í 6.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ÁßÁõ ÇãÇ÷¼º »çÁö Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

ÁßÁõ ÇãÇ÷¼º »çÁö Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡? ¸»Ãʵ¿¸ÆÁúȯ ȯÀÚ Áõ°¡¿¡ ´ëÇÑ ÀÌÇØ

¼¼°è ÁßÁõ ÇãÇ÷¼º ÇÏÁö(CLI) Ä¡·á ½ÃÀåÀº ¸»Ãʵ¿¸ÆÁúȯ(PAD), ´ç´¢º´, ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. CLI´Â PADÀÇ ÁßÁõÇüÀ̸ç, ÇÏÁöÀÇ Ç÷·ù °¨¼Ò¸¦ ÃÊ·¡Çϰí Á¾Á¾ Ä¡À¯µÇÁö ¾Ê´Â ±Ë¾ç, ±«Àú, Àý´Ü À§ÇèÀ» ÃÊ·¡ÇÕ´Ï´Ù. Àü ¼¼°è¿¡¼­ ¸¸¼ºÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í Á¦¾à ȸ»ç´Â ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ Ã·´Ü Ä¡·á ¿É¼Ç¿¡ ÁÖ¸ñÇϰí ÀÖ½À´Ï´Ù. Àα¸ °í·ÉÈ­, »ýȰ½À°ü °ü·Ã À§Çè¿äÀÎ, ºñ¸¸ Áõ°¡ µîÀ¸·Î ÀÎÇØ È¿°úÀûÀÎ CLI Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àúħ½ÀÀû Ç÷°ü³» Ä¡·á¿Í Àç»ýÀÇ·áÀÇ ¹ßÀüÀº CLI ȯÀڵ鿡°Ô »õ·Î¿î Èñ¸ÁÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù.

ÁßÁõ ÇãÇ÷¼º »çÁöÀÇ ÁÖ¿ä Ä¡·á¹ýÀº? ÁÖ¿ä ºÎ¹® »ìÆìº¸±â

CLI Ä¡·á ½ÃÀåÀº Ç÷ÇàÀç°Ç¼ú, ¾à¸®ÇÐÀû ÁßÀç, ½ÅÈï Àç»ý¿ä¹ý µî ´Ù¾çÇÑ Ä¡·á Á¢±Ù¹ýÀ¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. Ç÷°ü¼ºÇü¼úÀ̳ª ½ºÅÙÆ® »ðÀÔ¼ú°ú °°Àº Ç÷°ü³» Ä¡·á´Â CLI ȯÀÚÀÇ Ç÷·ù ȸº¹À» À§ÇÑ Ç¥ÁØ Ä¡·á¹ýÀ̸ç, »õ·Î¿î ¾à¹° ÄÚÆÃ Ç³¼± ±â¼úÀº Àå±âÀûÀÎ È¿°ú¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¿ìȸ¼ú°ú °°Àº ¿Ü°úÀû Ä¡·áµµ ÁßÁõ ȯÀÚ¿¡°Ô ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Ç×Ç÷¼ÒÆÇ ¿ä¹ý°ú Ç×ÀÀ°í ¿ä¹ýÀ» Æ÷ÇÔÇÑ ¾à¹° Ä¡·á´Â Áúº´ÀÇ ÁøÇàÀ» ¿¹¹æÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ Áٱ⼼Æ÷ Ä¡·á³ª À¯ÀüÀÚ ±â¹Ý Ä¡·á¿Í °°Àº Àç»ýÀÇ·á Á¢±Ù¹ýÀº Ç÷°ü Àç»ý°ú »óó Ä¡À¯¸¦ ÃËÁøÇÏ´Â µ¥ À¯¸Á °á°ú¸¦ º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á¿Í AI Áø´ÜÀÇ ÅëÇÕÀº Á¶±â¹ß°ß°ú ¸ÂÃãÇü Ä¡·á Àü·«À» ´õ¿í Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

±â¼úÀÌ CLI Ä¡·á¸¦ ¾î¶»°Ô º¯È­½Ãų °ÍÀΰ¡: AI, ¹ÙÀÌ¿À¼ÒÀç, ¸ÂÃãÇü ÀÇ·áÀÇ ¿ªÇÒ

CLI Ä¡·á ºÐ¾ß´Â ¹ÙÀÌ¿À¼ÒÀç, AI ±â¹Ý Áø´Ü, Á¤¹ÐÀÇ·áÀÇ ±â¼ú Çõ½ÅÀ¸·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. AI°¡ žÀçµÈ ¿µ»ó Áø´Ü ÅøÀº Ç÷°ü °Ç°­ »óŸ¦ ºÐ¼®Çϰí ÇãÇ÷ ºÎÀ§¸¦ º¸´Ù Á¤È®ÇÏ°Ô ÆÄ¾ÇÇÏ¿© Á¶±â ¹ß°ßÀ» °­È­ÇÕ´Ï´Ù. »ýü°øÇп¡ ÀÇÇÑ ÀΰøÇ÷°ü ¹× Á¶Á÷ ½ºÄ³Æú´õÀÇ °³¹ß·Î Ç÷·ù ȸº¹ÀÌ Àå±â°£ Áö¼ÓµÇ¾î Ä¡·á ¼ºÀûÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯ÀüÀÚ Ä¡·á¿Í Áٱ⼼Æ÷ À̽ÄÀÇ ¹ßÀüÀº Àý´ÜÀÇ Çʿ伺À» ÁÙÀÏ ¼ö ÀÖ´Â ÀáÀçÀûÀÎ Àç»ý ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¿þ¾î·¯ºí °Ç°­ ¸ð´ÏÅ͸µ ÀåÄ¡µµ Ç÷¾× ¼øÈ¯À» ÃßÀûÇÏ°í ½Ç½Ã°£ ȯÀÚ °ü¸®¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á°¡ È®»êµÊ¿¡ µû¶ó À¯ÀüÀÚ ¹× ´ë»ç ÇÁ·ÎÆÄÀÏ¿¡ ±â¹ÝÇÑ ¸ÂÃãÇü Ä¡·á Àü·«ÀÌ CLIÀÇ Ä¡·á È¿°ú¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

CLI Ä¡·á ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº? ÁÖ¿ä ½ÃÀå ¿µÇâ¿äÀÎ

ÁßÁõ ÇãÇ÷¼º »çÁö Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â ¿äÀÎÀ¸·Î´Â Áúº´ À¯º´·ü Áõ°¡, ÀÇ·áºñ ÁöÃâ Áõ°¡, Ç÷°ü³» Ä¡·á ¹× Àç»ý Ä¡·áÀÇ ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù. Ç÷°ü ¼ö¼ú ¹× ÁßÀçÀû ½ÉÀåÇÐ ÇÁ·Î±×·¥ÀÇ È®´ë·Î ÷´Ü CLI Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¶±â °ËÁø ¹× PAD¿¡ ´ëÇÑ ÀÎÁöµµ¸¦ ³ôÀ̱â À§ÇÑ Á¤ºÎÀÇ ±¸»óÀÌ Áø´ÜÀ² Çâ»ó¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °¡Ä¡ ±â¹Ý ÀÇ·á ¸ðµ¨ÀÇ ºÎ»óÀ¸·Î ºñ¿ë È¿À²ÀûÀÎ CLI Ä¡·á¹ý °³¹ßÀÌ ÃËÁøµÇ°í ÀÖÀ¸¸ç, ÃæºÐÇÑ ¼­ºñ½º¸¦ ¹ÞÁö ¸øÇÏ´Â »ç¶÷µé¿¡°Ôµµ Ä¡·á°¡ ´õ ½±°Ô ´Ù°¡°¥ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. »õ·Î¿î Ç÷°ü Àç»ý ±â¼úÀÇ Áö¼ÓÀûÀÎ ¿¬±¸¿Í ¼¼°è ÇコÄɾî ÀÎÇÁ¶óÀÇ È®ÀåÀ¸·Î CLI Ä¡·á ½ÃÀåÀº Å« ¹ßÀü°ú Àå±âÀûÀÎ ¼ºÀåÀ» ÀÌ·ê Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

DFU Ä¡·áÁ¦(â»ó ÇǺ¹Àç, »ý¹°Á¦Á¦, Ä¡·á ±â±â, Ç×»ýÁ¦ Á¦Á¦, ±âŸ DFU Ä¡·áÁ¦), DFU Ä¡·á ±Ë¾ç À¯Çü(½Å°æÀå¾Ö¼º ±Ë¾ç, ÇãÇ÷¼º ±Ë¾ç, ½Å°æÇãÇ÷¼º ±Ë¾ç), DFU Ä¡·á ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Critical Limb Ischemia Treatment Market to Reach US$8.1 Billion by 2030

The global market for Critical Limb Ischemia Treatment estimated at US$5.6 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Wound Care Dressings, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$2.8 Billion by the end of the analysis period. Growth in the Biologics segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 9.8% CAGR

The Critical Limb Ischemia Treatment market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Critical Limb Ischemia Treatment Market - Key Trends & Drivers Summarized

Why Is the Demand for Critical Limb Ischemia Treatment Increasing? Understanding the Rise in Peripheral Artery Disease Cases

The global critical limb ischemia (CLI) treatment market is witnessing rapid growth due to the increasing prevalence of peripheral artery disease (PAD), diabetes, and cardiovascular conditions. CLI is a severe form of PAD that leads to reduced blood flow in the lower extremities, often resulting in non-healing ulcers, gangrene, and amputation risks. As the global burden of chronic diseases rises, healthcare providers and pharmaceutical companies are focusing on advanced treatment options to improve patient outcomes. Aging populations, lifestyle-related risk factors, and the growing incidence of obesity have further fueled the demand for effective CLI therapies. Additionally, advancements in minimally invasive endovascular procedures and regenerative medicine have provided new hope for CLI patients.

What Are the Leading Treatment Options for Critical Limb Ischemia? Exploring Key Segments

The CLI treatment market consists of various therapeutic approaches, including revascularization procedures, pharmacological interventions, and emerging regenerative therapies. Endovascular treatments, such as angioplasty and stent placement, remain the gold standard for restoring blood flow in CLI patients, with newer drug-coated balloon technologies enhancing long-term efficacy. Surgical interventions, including bypass grafting, are also widely used for severe cases. Pharmacological treatments, including antiplatelet and anticoagulant therapies, play a critical role in preventing disease progression. Additionally, regenerative medicine approaches, such as stem cell therapy and gene-based treatments, have shown promising results in promoting vascular regeneration and wound healing. The integration of telemedicine and AI-driven diagnostics is further improving early detection and personalized treatment strategies.

How Is Technology Transforming CLI Treatment? The Role of AI, Biomaterials & Personalized Medicine

The field of CLI treatment is evolving with technological innovations in biomaterials, AI-driven diagnostics, and precision medicine. AI-powered imaging tools are enhancing early detection by analyzing vascular health and identifying ischemic regions with greater accuracy. The development of bioengineered vascular grafts and tissue scaffolds has improved treatment outcomes by providing long-lasting blood flow restoration. Additionally, advances in gene therapy and stem cell transplantation are offering potential regenerative solutions, reducing the need for amputation. Wearable health monitoring devices are also playing a role in tracking blood circulation, enabling real-time patient management. As personalized medicine gains traction, tailored therapeutic strategies based on genetic and metabolic profiles are improving CLI treatment efficacy.

What’s Driving the Growth of the CLI Treatment Market? Key Market Influencers Explained

The growth in the critical limb ischemia treatment market is driven by increasing disease prevalence, rising healthcare expenditures, and advancements in endovascular and regenerative therapies. The expansion of vascular surgery and interventional cardiology programs has improved access to advanced CLI treatments. Additionally, government initiatives promoting early screening and PAD awareness have contributed to higher diagnosis rates. The rise of value-based healthcare models has encouraged the development of cost-effective CLI therapies, making treatment more accessible to underserved populations. With continued research in novel vascular regeneration techniques and expanding global healthcare infrastructure, the CLI treatment market is poised for significant advancements and long-term growth.

SCOPE OF STUDY:

The report analyzes the Critical Limb Ischemia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

DFU Treatment (Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications, Other DFU Treatments); DFU Treatment Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, Neuro-ischemic Ulcers); DFU Treatment End-Use (Hospital End-Use, Ambulatory Surgery Centre End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â